Do you want to contribute to improving human health?

The Department of Oncology and Pathology’s mission is to improve diagnostics, treatment and quality of life for patients with cancer through basic, translational and clinical research and education in the field of cancer. We want to achieve excellence in research and education, foster clinical research and create high technology platforms for research support and innovation. In that we value ethics, high diversity and equality; cultivate openness networking and collaborations to consolidate national and international forces to cure cancer.

Our research focuses on the development of radiopharmaceuticals for precision diagnostics, therapy and monitoring of cancer diseases, so called theranostics.

We conduct studies including cyclotron production of radiometals using solid target, novel radiopharmaceutical developments, biological evaluation studies in vitro and in vivo using different cancer models, to clinical translation. In close collaborations with oncologists and radiologists, we perform several clinical studies (first-in-human, phase I/II studies) of different radiopharmaceuticals.

Your mission

The radiopharmaceuticals we develop for diagnostics are labelled with radiometals for PET (positron emission tomography) imaging while for therapeutic applications, they will be labelled with alpha or beta emitters.

We are now looking for a driven, curious individual who wants to contribute to the development of small-peptide and monoclonal antibody-based radiopharmaceuticals for improving diagnostics and therapy effects of metastatic cancer diseases. The work will include radiolabelling, quality control using analytical methods such as HPLC and TLC, in vitro cell binding assays and animal studies.

Your profile

We are looking for someone with a MSc degree in applied life sciences such as Radiopharmacy, Pharmacy, Drug Development, Biomedicine, Biology or equivalent.

Who are you?

  • A curious, driven person who are able to work independently after some training.
  • You possess analytical skills of HPLC and TLC instrumentations for characterization of small peptides and monoclonal antibodies.
  • Solid experiences of work with radiation, cell culture and animal studies are of merits.
  • A person who takes initiative while being a collaborative team player and contributes to the team.
  • In this recruitment we put high preference on the personal suitability. 

What do we offer?

A creative and inspiring environment with wide-ranging expertise and interests. Karolinska Institutet is one of the world's leading medical universities. Our vision is to pursue the development of knowledge about life and to promote a better health for all. At Karolinska Institutet, we conduct successful medical research and hold the largest range of medical education in Sweden. Karolinska Institutet is also a state university, which entitles you to several good benefits through our collective agreement. And you get to practice freely in our modern wellness facilities, where trained staff are on site.

Location: BioClinicum, Solna

Choose to work at KI – Ten reasons why

Application

Welcome to apply at the latest 26th May.

The application is to be submitted through the Varbi recruitment system.In this recruitment, you will apply with your CV without a personal letter. Instead, you will answer some questions about why you are applying for the job in the application form. 

The employment is maximum 1 year. 

Want to make a difference? Join us and contribute to better health for all

Type of employment Temporary position
Contract type Full time
First day of employment Up on agreement
Salary Monthly salary
Number of positions 1
Full-time equivalent 100 %
City Solna
County Stockholms län
Country Sweden
Reference number STÖD 2-1983/2023
Contact
  • Thuy Tran, thuy.tran@ki.se
Union representative
  • Helen Eriksson, OFR, helen.eriksson@ki.se
  • Henry Wölling, henry.wolling@ki.se
  • Per Hydbring/Nick Tobin, Saco, per.hydbring@ki.se/nick.tobin@ki.se
Published 12.May.2023
Last application date 26.May.2023 11:59 PM CEST

Return to job vacancies